Biohaven Ltd. (NYSE:BHVN – Get Free Report) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 9,260,000 shares, a decline of 5.8% from the May 31st total of 9,830,000 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is presently 6.8 days.
Biohaven Price Performance
Shares of NYSE BHVN opened at $33.79 on Thursday. Biohaven has a 1 year low of $16.45 and a 1 year high of $62.21. The firm has a 50-day moving average of $36.25 and a 200 day moving average of $43.94.
Biohaven (NYSE:BHVN – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($2.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.50) by ($0.70). On average, equities analysts forecast that Biohaven will post -7.16 EPS for the current year.
Insider Transactions at Biohaven
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the business. Thompson Davis & CO. Inc. purchased a new position in Biohaven in the fourth quarter worth about $214,000. Prevail Innovative Wealth Advisors LLC purchased a new position in Biohaven in the fourth quarter worth about $230,000. Private Advisor Group LLC purchased a new position in Biohaven in the fourth quarter worth about $231,000. Capstone Investment Advisors LLC purchased a new position in Biohaven in the fourth quarter worth about $235,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Biohaven in the third quarter worth about $236,000. 88.78% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
BHVN has been the topic of a number of recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $59.00 price target on shares of Biohaven in a report on Tuesday, June 18th. HC Wainwright reissued a “buy” rating and issued a $59.00 price target on shares of Biohaven in a report on Thursday, May 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a report on Thursday, May 30th. Finally, UBS Group raised their price target on shares of Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $54.71.
Get Our Latest Analysis on Biohaven
About Biohaven
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
See Also
- Five stocks we like better than Biohaven
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What is the S&P/TSX Index?
- AbbVie Stock: A Perfect Dip for Investors to Buy
- How to Invest in Insurance Companies: A GuideĀ
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.